US-based pharmaceutical firm Pneuma Respiratory has developed a fully digital, soft mist inhaler device designed to deliver a variety of medicines to the lungs.

The inhaler uses electronic breath actuation and a soft mist ejector, which can sense the breath and automatically activate upon inhalation by a patient.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The need for a propellant is eliminated as the ejector automatically delivers medication droplets into the lungs through the patient’s breath.

The device is accompanied by a mobile application that captures real-time dose verification data.

Pneuma Respiratory business development director James Bauler said: “It’s well documented that patients have problems adopting the correct inhaler technique and thus receiving the expected dose of medication both with dry powder and existing metered-dose inhalers.

“With a proven team of technology and healthcare leaders, Pneuma expects to make significant gains in pulmonary drug delivery.”

The inhaler has already been evaluated in two clinical studies by using bronchodilation as the outcome.

“With a proven team of technology and healthcare leaders, Pneuma expects to make significant gains in pulmonary drug delivery.”

According to the results, the device demonstrated effective delivery of medicines to the lungs in chronic obstructive pulmonary disease (COPD) patients who are using small-molecule asthma and COPD medications.

The device is also reported to have delivered large, complex, pharmacologically intact biologics during preclinical binding studies.

Pneuma Respiratory focuses on working towards new therapeutic treatments for lung diseases.

The firm holds experience in healthcare research and product development, along with handheld device design and manufacturing expertise.